Gunhild von Amsberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gunhild von Amsberg has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Anja Lorch
Department of Urology, University Hospital, Duesseldorf, Germany
18 shared publications - Aurelius Omlin
Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland
18 shared publications - Axel Heidenreich
Department of Urology, Urologic Oncology, Robot‐Assisted and Specialized Urologic Surgery University of Cologne Cologne Germany
18 shared publications - Christoph Reuter
University Hospital, Hannover, Germany
18 shared publications - Igor Tsaur
Department of Urology and Pediatric Urology, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
18 shared publications - Julian Larcher-Senn
Assign Data Management and Biostatistics GmbH, 6020 Innsbruck, Austria
18 shared publications
Latest Publications
- 27 April 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (13) , 2527-2529
Targeted Radiation, Unintended Evolution
Summary: Radioligand therapy exemplifies precision oncology, yet its consequences remain incompletely understood. A recent article shows that [177Lu]Lu-PSMA promotes emergence and expansion of clonal hematopoiesis enriched for DNA damage response gene mutations, reframing bone marrow effects as treatment-emergent clonal selection rather than collateral toxicity and informing biology-guided patient monitoring and theranostics. See related article by Munzur et al., p. 2644
- 27 April 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (13) , 2527-2529
Targeted Radiation, Unintended Evolution
Summary: Radioligand therapy exemplifies precision oncology, yet its consequences remain incompletely understood. A recent article shows that [177Lu]Lu-PSMA promotes emergence and expansion of clonal hematopoiesis enriched for DNA damage response gene mutations, reframing bone marrow effects as treatment-emergent clonal selection rather than collateral toxicity and informing biology-guided patient monitoring and theranostics. See related article by Munzur et al., p. 2644
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Purpose:There is ongoing controversy about the recommended dose of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods:This multicenter phase II open-label, randomized, parallel-group study compared 3-weekly cabazitaxel at 25 mg/m2 (conventional arm A) with cabazitaxel therapeutic drug monitoring (experimental arm B) in mCRPC. The primary objective was to improve the clinical feasibility rate (CFR), defined as the absence of grade 4 neutropenia or thrombocytopenia, any thrombocytopenia with bleeding, febrile neutropenia, severe nonhematologic toxicity, withdrawal for cabazitaxel-related toxicity, or death. A total of 60 patients had to be randomized to detect a difference in CFR of 35% (power 80%, two-sided alpha 10%).Results:A total of 40 patients were randomized to arm A and 33 patients to arm B. CFR was 69.4% in arm A and 64.3% in arm B (P = 0.79). Week-12 PSA response was 38.5% in both arms. A radiological response by RECIST v.1.1 was seen in 3 (9.7%) patients in arm A versus 6 (23.1%) patients in arm B (P = 0.28), disease progression was higher in arm A compared with arm B (61.3% vs. 30.8%, P = 0.05). Median progression-free survival was longer in arm B compared with arm A (9.5 vs. 4.4 months; HR = 0.46; P = 0.005). Median overall survival was higher in arm B compared with arm A (16.2 vs. 7.3 months; HR = 0.33; P < 0.0001).Conclusions:Pharmacokinetic-guided dosing of cabazitaxel in patients with mCRPC is feasible and improves clinical outcome due to individual dose escalations in 55% of patients.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
Purpose:There is ongoing controversy about the recommended dose of cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).Patients and Methods:This multicenter phase II open-label, randomized, parallel-group study compared 3-weekly cabazitaxel at 25 mg/m2 (conventional arm A) with cabazitaxel therapeutic drug monitoring (experimental arm B) in mCRPC. The primary objective was to improve the clinical feasibility rate (CFR), defined as the absence of grade 4 neutropenia or thrombocytopenia, any thrombocytopenia with bleeding, febrile neutropenia, severe nonhematologic toxicity, withdrawal for cabazitaxel-related toxicity, or death. A total of 60 patients had to be randomized to detect a difference in CFR of 35% (power 80%, two-sided alpha 10%).Results:A total of 40 patients were randomized to arm A and 33 patients to arm B. CFR was 69.4% in arm A and 64.3% in arm B (P = 0.79). Week-12 PSA response was 38.5% in both arms. A radiological response by RECIST v.1.1 was seen in 3 (9.7%) patients in arm A versus 6 (23.1%) patients in arm B (P = 0.28), disease progression was higher in arm A compared with arm B (61.3% vs. 30.8%, P = 0.05). Median progression-free survival was longer in arm B compared with arm A (9.5 vs. 4.4 months; HR = 0.46; P = 0.005). Median overall survival was higher in arm B compared with arm A (16.2 vs. 7.3 months; HR = 0.33; P < 0.0001).Conclusions:Pharmacokinetic-guided dosing of cabazitaxel in patients with mCRPC is feasible and improves clinical outcome due to individual dose escalations in 55% of patients.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Figure S5: Expression of GLUT-1 in different prostate cancer cell lines
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Figure S5: Expression of GLUT-1 in different prostate cancer cell lines
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Figure S2: Effect of PeS-9 on AR-FL and AR-V7 mRNA expression in 22Rv1 cells
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Figure S2: Effect of PeS-9 on AR-FL and AR-V7 mRNA expression in 22Rv1 cells
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Table S3: Spectral data of the synthesized compounds
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Table S3: Spectral data of the synthesized compounds
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Table S2: Synthesized compounds
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Table S2: Synthesized compounds
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Figure S4: Expression of GLUT-1 and GLUT-4 mRNA in different prostate cancer cell lines examined using RT-qPCR
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Figure S4: Expression of GLUT-1 and GLUT-4 mRNA in different prostate cancer cell lines examined using RT-qPCR
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Table S4: List of antibodies used for Western blotting
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from 6-[(1,4-Naphthoquinone-2-yl)methyl]thio–Glucose Conjugates, a Novel Targeted Approach for Advanced Prostate Cancer
Supplementary Table S4: List of antibodies used for Western blotting